期刊文献+

血管紧张素转换酶基因多态性与肺癌关系的研究 被引量:2

Analysis of the relationship between polymorphism of angiotensin-converting enzyme gene and lung cancer
下载PDF
导出
摘要 背景与目的血管紧张素转换酶(ACE)是RAS系统的关键酶,在肺内表达丰富。近年来的研究发现ACE有着广泛的生理作用,包括参与肿瘤发生和发展的病理过程。本研究拟探讨ACE基因内一287bp的片段插入(insertion,I)与缺失(deletion,D)多态性是否与肺癌的易感性、病理类型和临床分期存在相关性。方法从47例肺癌患者和54例正常对照者的外周静脉血中提取DNA,采用PCR方法测定基因型。结果肺癌组中II、ID和DD基因型频率分别为0.447、0.447和0.106,I和D等位基因的频率分别为0.670和0.330;正常对照组中II、ID和DD基因型频率分别为0.370、0.556和0.074,I和D等位基因的频率分别为0.648和0.352,两组间各基因型和等位基因的分布无显著统计学差异(P>0.05)。小细胞与非小细胞肺癌患者间以及各临床分期间也未发现ACE基因型和等位基因分布的差异(P>0.05)。结论本研究未发现ACE的基因多态性与肺癌的易感性、病理类型或临床分期存在相关性。 Background and objective Angiotensin-converting enzyme (ACE), the key enzyme of RAS, is expressed in abundance in lung. Recent studies show that it plays various biological roles and even contributes importantly to the carcinogenesis of malignant tumors. The aim of this study is to investigate whether the insertion (I)/deletion (D) polymorphism of ACE is related to the susceptibility, pathological type or staging of lung cancer. Methods DNA was extracted from the peripheral veinous blood derived from 47 lung cancer patients and 54 normal persons. The ACE genotype of each sample was amplified with PCR. Results The frequencies of II, ID and DD genotype of ACE in lung cancer group were 0.447, 0.447 and 0.106 respectively, and the frequencies of I and D allele were 0.670 and 0.330 respectively. The frequencies of II, ID and DD geno-(type) of ACE in control group were 0.370, 0.556 and 0.074 respectively, and the frequencies of I and D allele were 0.648 and 0.352 respectively. There was no significant difference of ACE genotypes or alleles frequencies between the lung cancer and control groups. No significant difference of ACE genotypes or alleles frequencies was found between small cell lung cancer and non-small cell lung cancer groups or between the different staging groups of lung cancer patients. Conclusion No association is found between the polymorphism of ACE gene and the susceptibility, pathological type or clinical staging of lung cancer.
出处 《中国肺癌杂志》 CAS 2005年第3期211-214,共4页 Chinese Journal of Lung Cancer
基金 首都医学发展科研基金(No.20021016)资助
关键词 血管紧张素转换酶 血管紧张素Ⅱ 基因多态性 肺肿瘤 Angiotensin-converting enzyme AngiotensinⅡ Gene polymorphism Lung neoplasms
  • 相关文献

参考文献19

  • 1Lindberg H, Nielsen D, Jensen BV, et al. Angiotensin converting enzyme inhibitors for cancer treatment? Acta Oncol, 2004,43(2):142-152.
  • 2de Groot-Besseling RR, Ruers TJ, van Kraats AA, et al. Anti tumor activity of a combination of plasminogen activator and capto pril in a human melanoma xenograft model. Int J Cancer, 2004,112(2): 329-334.
  • 3Noguchi R, Yoshiji H, Kuriyama S, et al. Combination of interferon beta and the angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma development and angiogenesis. Clin Cancer Res,2003,9(16 Pt 1): 6038-6045.
  • 4Yasumaru M, Tsuji S, Tsujii M, et al. Inhibition of angiotensin Ⅱ activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor Ⅰ receptor pathway. Cancer Res,2003,63 (20) : 6726-6734.
  • 5Medeiros R, Vasconcelos A, Costa S, et al. Linkage of angiotensin Ⅰ -converting enzyme gene insertion/deletion polymorphism to the progression of human prostate cancer. J Pathol, 2004, 202(3): 330-335.
  • 6Koh WP, Yuan JM, Sun CL, et al. Angiotensin Ⅰ -converting enzyme (ACE) gene polymorphism and breast cancer risk among Chi nese women in Singapore. Cancer Res,2003,63(3): 573 578.
  • 7Yoshiji H, Yoshii J, Ikenaka Y, et al. Suppression of the reninangiotensin system attenuates vascular endothelial growth factor mediated tumor development and angiogenesis in murine hepatocellular carcinoma cells. Int J Oncol,2002,20(6) : 1227-1231.
  • 8Yoshiji H, Kuriyama S, Fukui H. Perindopril: possible use in cancer therapy. Anticancer Drugs,2002,13(3) :221-228.
  • 9Walther T, Menrad A, Orzechowski HD, et al. Differential regulation of in vivo angiogenesis by angiotensin Ⅱ receptors. FASEB J,2003,17 (14): 2061-2067.
  • 10Molteni A, Ward WF, Ts'ao CH, et al. Cytostatic properties of some angiotensin Ⅰ converting enzyme inhibitors and of angioten sin Ⅱ type Ⅰ receptor antagonists. Curr Pharm Des,2003,9(9):751-761.

二级参考文献3

共引文献1

同被引文献27

  • 1高社军,郭明卫,雍兰娜,王星冀,洪文竹,胡邑姜.4种肺部疾病血清血管紧张素Ⅱ转换酶活性的比较[J].临床检验杂志,2005,23(4):300-301. 被引量:6
  • 2Medeiros R,Vasconcelos A,Costa S,et al.Linkage of angiotensin Ⅰ converting enzyme gene insertion/deletion polymorphism to the progression of human prostate cancer[J].J Pathol,2004,202(3):330-335.
  • 3Koh WP,Yuan JM,Sun CL,et al.Angiotensin Ⅰ converting enzyme(ACE)gene polymorphism and breast cancer risk among Chinese women in Singapore[J].Cancer Res,2003,63 (3):573-578.
  • 4Zou JH,An L,Chen S,et al.XPA A23G polymorphism and lung cancer risk:a meta-analysis[J].Mol Biol Rep,2012,39(2):1435-1440.
  • 5Lindberg H,Nielsen D,Jensen BV,et al.Angiotensin conv erting enzyme inhibitors for cancer treatment.?[J].ActaOncol,2004,43(5):142-152.
  • 6Molteni A,Ward WF,Tsao CH,et al.Cytostatic properties of some angiotensin Ⅰ converting enzyme inhibitors and of angiotensin]Ⅱ type Ⅰ receptor antagonists[J].Curr Pharm Des,2003,9(9):751-761.
  • 7Yasumaru M,Tsuji S,Tsujii M,et al.Inhibition of angiotensin]Ⅱ activity enhanced the antitumor effect of cyclooxygenase 2 inhibitors via insulin-like growth fac tor Ⅰ receptor pathway[J].Cancer Res,2003,63 (20):6726-6734.
  • 8Gao M,Wang Y,Shi Y,et al.The relationship between three well-characterized polymorphisms of the angiotensin converting enzyme gene and lung cancer risk:a casecontrol study and a meta-analysis[J].J Renin Angiotensin Aldosterone Syst,2012,13 (4):455-46.
  • 9Devic PS,Ristic S,Flego V,et al.Angiotensin-converting enzyme insertion/deletion gene polymorphism in lung cancer patients[J].Genet Test Mol Biomarkers,2012,16 (7):722-725.
  • 10Pharoach PD,Dunning AM,Ponder BA,et al.Association studies for finding cancer-susceptibility genetic varians[J].Nat Rev Cancer,2004,4(8):850-860.

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部